Scilex entered into a MOU for collaboration agreement with ACEA

Scilex Holding announced that that it has entered into a Memorandum of Understanding, MOU, for collaboration agreement with ACEA, a China-based company focused on the development of innovative treatments for high unmet needs. Under the terms of the MOU, ACEA may receive exclusive rights to develop and commercialize of ZTlido in mainland China, Taiwan, Hong Kong, Macau, including the current formulation and a right of first negotiation for a future next generation formulation of a 3X version of ZTlido, SP-103. The MOU provides Scilex with the opportunity to expand collaboration with ACEA across other products in Scilex’s non-opioid pain management portfolio in the Greater China region. “This joint collaboration effort with ACEA reflects on our mission to bring our innovative non-opioid medicines to acute and chronic pain patients in greater China region. This agreement is an important step toward our shared goal of bringing safe and effective pain management to people worldwide, to ensure more patients are able to benefit from these innovative medicines,” said Jaisim Shah, Chief Executive Officer and President of Scilex.